试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Novel Induction to Buprenorphine/Naloxone
编号:NCT05644587登记状态:提前终止企业 / 申办者:Bicycle Health
药物 / 成分:buprenorphine/naloxone
登记的停止原因(原文):Low enrollment numbers
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
编号:NCT05849246登记状态:提前终止企业 / 申办者:Innovent Biologics (Suzhou) Co. Ltd.
药物 / 成分:Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed、Sintilimab+Carboplatin or Cisplatin+Pemetrexed、Tusamitamab ravtansine+Sintilimab
登记的停止原因(原文):strategy terminates development, the decision is not due to any safety-related issues
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-19
Optimal Treatment of Veterans With PTSD and Comorbid OUD
编号:NCT03605342登记状态:提前终止企业 / 申办者:VA Office of Research and Development
药物 / 成分:Buprenorphine、Cognitive Processing Therapy (CPT)、Individual Drug Counseling (IDC)
登记的停止原因(原文):Early termination
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-19
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
编号:NCT03850795登记状态:提前终止企业 / 申办者:Hinova Pharmaceuticals USA, Inc.
药物 / 成分:HC-1119、Enzalutamide
登记的停止原因(原文):Terminated by Sponsor for various factors including prolonged duration and enrollment challenges
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-19
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
编号:NCT05251727登记状态:提前终止企业 / 申办者:Asahi Kasei Therapeutics, Inc.
药物 / 成分:thrombomodulin alfa、Placebo
登记的停止原因(原文):Business Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-19
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
编号:NCT05569512登记状态:提前终止企业 / 申办者:Malika Kapadia
药物 / 成分:Uproleselan、Fludarabine、Clofarabine、Busulfan
登记的停止原因(原文):On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-19
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
编号:NCT06102213登记状态:提前终止企业 / 申办者:Prolacta Bioscience
药物 / 成分:B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)
登记的停止原因(原文):Sponsor business decision to terminate the study early
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-16
IW-6463 Safety Study in Healthy Elderly Subjects
编号:NCT04240158登记状态:提前终止企业 / 申办者:Tisento Therapeutics
药物 / 成分:IW-6463、Matching Placebo
登记的停止原因(原文):Some subjects could not complete the second crossover period due to COVID-19-related site closure. The study was closed to allow analysis of all collected data.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
编号:NCT04594811登记状态:提前终止企业 / 申办者:NeoImmuneTech
药物 / 成分:NT-I7、Nivolumab
登记的停止原因(原文):Company strategic decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-16
Empagliflozin for the Treatment of Postprandial Hypoglycemia
编号:NCT05036317登记状态:提前终止企业 / 申办者:University Hospital, Basel, Switzerland
药物 / 成分:Empagliflozin (Jardiance®;、Placebo Control Intervention
登记的停止原因(原文):Early terminated after prespecified interim analysis due to lack of efficacy. No relevant safety signals.
查看官方原始记录 ↗